Impact of COVID-19 on Outcomes of Patients with Hematologic Malignancies: A Multicenter, Retrospective Study

• Published in: Mediterranean journal of hematology and infectious diseases 2022-11, Vol.14 (1), p.e2022074-e2022074
• Main Authors: Acar, Ibrahim Halil, Guner, Sebnem Izmir, Ak, Muzeyyen Aslaner, Gocer, Mesut, Ozturk, Erman, Atalay, Figen, Sincan, Gulden, Yikilmaz, Aysun Senturk, Ekinci, Omer, Ince, Idris, Gulturk, Emine, Demir, Nazli, Dogan, Ali, Ipek, Yildiz, Guvenc, Birol
• Format: Article
• Language: English
• Subjects: Original
• ISSN: 2035-3006; 2035-3006
• DOI: 10.4084/MJHID.2022.074

ObjectivesPatients with hematological malignancies have a high risk of mortality from coronavirus disease 2019 (COVID-19). This study aimed to investigate the impact of COVID-19 on mortality rates in patients with various hematological malignancies and to determine risk factors associated with all-cause mortality. MethodsA multicenter, observational retrospective analysis of patients with hematological malignancies infected with COVID-19 between July 2020 and December 2021 was performed. Demographic data, clinical characteristics, and laboratory parameters were recorded. Patients were grouped as non-survivors and survivors. All-cause mortality was the primary outcome of the study. ResultsThere were 569 patients with a median age of 59 years. Non-Hodgkin lymphoma (22.0%) and multiple myelomas (18.1%) were the two most frequent hematological malignancies. The all-cause mortality rate was 29.3%. The highest mortality rates were seen in patients with acute myeloid leukemia (44.3%), acute lymphoid leukemia (40.5%), and non-Hodgkin lymphoma (36.8%). The non-survivors were significantly older (p